In this video, Motley Fool health-care analyst David Williamson discusses Spectrum Pharmaceuticals (NASDAQ:SPPI), and why more than 50% of the stock's float is sold short. The company took off in 2011, when production problems with the generic drug Leucovorin gave it a chance to get doctors to switch to its more expensive branded drug, Fusilev, but sales of Fusilev have flagged lately. David tells investors whether Fusilev's days of sales growth are over, and what else Spectrum has up its sleeve that may prove the shorts wrong.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Biotech Stocks to Be Thankful for This Year
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum's preliminary lung cancer data sparked a noteworthy rally in its shares last month.
3 Healthcare Stocks That Soared This Week: Are They Buys?
Can the sizzling momentum continue for TransEnterix, uniQure, and Spectrum Pharmaceuticals?